Carlos E RodrÃ-guez-MartÃ-nez

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8407104/publications.pdf

Version: 2024-02-01



Carlos E

#	Article	IF	CITATIONS
1	Risk and Protective Factors for Childhood Asthma: What Is the Evidence?. Journal of Allergy and Clinical Immunology: in Practice, 2016, 4, 1111-1122.	3.8	177
2	Decontamination and reuse of N95 filtering facemask respirators: A systematic review of the literature. American Journal of Infection Control, 2020, 48, 1520-1532.	2.3	87
3	Predictors of severity and mortality in children hospitalized with respiratory syncytial virus infection in a tropical region. Pediatric Pulmonology, 2014, 49, 269-276.	2.0	72
4	Prevalence of and factors associated with current asthma symptoms in school children aged 6–7 and 13–14 yr old in BogotÃį, Colombia. Pediatric Allergy and Immunology, 2008, 19, 307-314.	2.6	49
5	The relationship between inflammation and remodeling in childhood asthma: A systematic review. Pediatric Pulmonology, 2018, 53, 824-835.	2.0	47
6	Factors predicting persistence of early wheezing through childhood and adolescence: a systematic review of the literature. Journal of Asthma and Allergy, 2017, Volume10, 83-98.	3.4	42
7	Discriminative properties of two predictive indices for asthma diagnosis in a sample of preschoolers with recurrent wheezing. Pediatric Pulmonology, 2011, 46, 1175-1181.	2.0	40
8	Cost-Utility Analysis of the Inhaled Steroids Available in a Developing Country for the Management of Pediatric Patients with Persistent Asthma. Journal of Asthma, 2013, 50, 410-418.	1.7	35
9	Daily inhaled corticosteroids or montelukast for preschoolers with asthma or recurrent wheezing: A systematic review. Pediatric Pulmonology, 2018, 53, 1670-1677.	2.0	34
10	Characterization of Cytomegalovirus Lung Infection in Non-HIV Infected Children. Viruses, 2014, 6, 2038-2051.	3.3	27
11	Respiratory syncytial virus, adenoviruses, and mixed acute lower respiratory infections in children in a developing country. Journal of Medical Virology, 2015, 87, 774-781.	5.0	27
12	Premature infants have impaired airway antiviral IFNÎ ³ responses to human metapneumovirus compared to respiratory syncytial virus. Pediatric Research, 2015, 78, 389-394.	2.3	26
13	Cost Effectiveness of Pharmacological Treatments for Asthma: A Systematic Review. Pharmacoeconomics, 2018, 36, 1165-1200.	3.3	21
14	Principal findings of systematic reviews of acute asthma treatment in childhood. Journal of Asthma, 2015, 52, 1038-1045.	1.7	20
15	Clinical Definition of Respiratory Viral Infections in Young Children and Potential Bronchiolitis Misclassification. Journal of Investigative Medicine, 2018, 66, 46-51.	1.6	20
16	Costâ€utility analysis of daily versus intermittent inhaled corticosteroids in mildâ€persistent asthma. Pediatric Pulmonology, 2015, 50, 735-746.	2.0	18
17	Systematic review of instruments aimed at evaluating the severity of bronchiolitis. Paediatric Respiratory Reviews, 2018, 25, 43-57.	1.8	18
18	Principal findings of systematic reviews for the management of acute bronchiolitis in children. Paediatric Respiratory Reviews, 2015, 16, 267-275.	1.8	17

#	Article	IF	CITATIONS
19	Predictors of Inappropriate Use of Diagnostic Tests and Management of Bronchiolitis. BioMed Research International, 2017, 2017, 1-6.	1.9	17
20	Predictors of Prolonged Length of Hospital Stay for Infants with Bronchiolitis. Journal of Investigative Medicine, 2018, 66, 986-991.	1.6	17
21	Predictors of hospitalization for asthma in children: Results of a 1-year prospective study. Pediatric Pulmonology, 2014, 49, 1058-1064.	2.0	16
22	Validation of the Spanish version of the childhood asthma control test (cACT) in a population of Hispanic children. Journal of Asthma, 2014, 51, 855-862.	1.7	16
23	Impact of the implementation of an evidence-based guideline on diagnostic testing, management, and clinical outcomes for infants with bronchiolitis. Therapeutic Advances in Respiratory Disease, 2016, 10, 425-434.	2.6	16
24	Human Metapneumovirus Infection is Associated with Severe Respiratory Disease in Preschool Children with History of Prematurity. Pediatrics and Neonatology, 2016, 57, 27-34.	0.9	16
25	Cost–utility analysis of once-daily versus twice-daily inhaled corticosteroid dosing for maintenance treatment of asthma in pediatric patients. Journal of Asthma, 2016, 53, 538-545.	1.7	15
26	Bronchodilators should be considered for all patients with acute bronchiolitis, but closely monitored for objectively measured clinicalÂbenefits. Acta Paediatrica, International Journal of Paediatrics, 2015, 104, 858-860.	1.5	14
27	Predictors of severe disease in a hospitalized population of children with acute viral lower respiratory tract infections. Journal of Medical Virology, 2016, 88, 754-759.	5.0	14
28	The impact of viral bronchiolitis phenotyping: Is it time to consider phenotype-specific responses to individualize pharmacological management?. Paediatric Respiratory Reviews, 2020, 34, 53-58.	1.8	14
29	Principal findings of systematic reviews for chronic treatment in childhood asthma. Journal of Asthma, 2015, 52, 407-416.	1.7	13
30	Meteredâ€dose inhalers vs nebulization for the delivery of albuterol in pediatric asthma exacerbations: A costâ€effectiveness analysis in a middleâ€income country. Pediatric Pulmonology, 2020, 55, 866-873.	2.0	13
31	Commercial versus home-made spacers in delivering bronchodilator therapy for acute therapy in children. The Cochrane Library, 2008, , CD005536.	2.8	12
32	Validation of the Spanish Version of the Test for Respiratory and Asthma Control in Kids (TRACK) in a Population of Hispanic Preschoolers. Journal of Allergy and Clinical Immunology: in Practice, 2014, 2, 326-331.e3.	3.8	12
33	Phenotypical Sub-setting of the First Episode of Severe Viral Respiratory Infection Based on Clinical Assessment and Underlying Airway Disease: A Pilot Study. Frontiers in Pediatrics, 2020, 8, 121.	1.9	12
34	Cost utility of fractional exhaled nitric oxide monitoring for the management of children asthma. Cost Effectiveness and Resource Allocation, 2021, 19, 33.	1.5	12
35	Meteredâ€dose inhalers versus nebulization for the delivery of albuterol for acute exacerbations of wheezing or asthma in children: A systematic review with metaâ€analysis. Pediatric Pulmonology, 2020, 55, 3268-3278.	2.0	11
36	The costâ€utility of intravenous magnesium sulfate for treating asthma exacerbations in children. Pediatric Pulmonology, 2020, 55, 2610-2616.	2.0	11

IF # ARTICLE CITATIONS Airway Remodeling Factors During Early-Life Rhinovirus Infection and the Effect of Premature Birth. Frontiers in Pediatrics, 2021, 9, 610478. For which infants with viral bronchiolitis could it be deemed appropriate to use albuterol, at least 38 1.7 10 on a therapeutic trial basis?. Allergologia Et Immunopathologia, 2021, 49, 153-158. Early Microbial–Immune Interactions and Innate Immune Training of the Respiratory System during 1.5 Health and Disease. Children, 2021, 8, 413. A systematic review of instruments aimed at evaluating metered-dose inhaler administration 40 1.7 9 technique in children. Journal of Asthma, 2017, 54, 173-185. Predictors of prolonged length of hospital stay or readmissions for acute viral lower respiratory tract infections among infants with a history of bronchopulmonary dysplasia. Journal of Medical 5.0 Virology, 2018, 90, 405-411. Predictors of hospitalization for acute lower respiratory infections during the first two years of 42 life in a population of preterm infants with bronchopulmonary dysplasia. Early Human Development, 1.8 9 2018, 127, 53-57. The use of Î²₂-adrenoreceptor agonists in viral bronchiolitis: scientific rationale beyond 2.6 evidence-based guidelines. ERJ Open Research, 2020, 6, 00135-2020. Costâ€utility of tiotropium for children with severe asthma in patients aged 1–5 years. Pediatric Allergy 44 2.6 9 and Immunology, 2021, 32, 1866-1868. The cost-utility of early use of high-flow nasal cannula in bronchiolitis. Health Economics Review, 2021, 11, 41. Cost-Effectiveness Analysis of Mometasone Furoate Versus Beclomethasone Dipropionate for the 46 2.9 8 Treatment of Pediatric Allergic Rhinitis in Colombia. Advances in Therapy, 2015, 32, 254-269. Leukotriene receptor antagonists as maintenance or intermittent treatment in pre-school children 1.8 with episodic viral wheeze. Paediatric Respiratory Reviews, 2016, 17, 57-59. Quality assessment of acute viral bronchiolitis clinical practice guidelines. Journal of Evaluation in 48 1.8 8 Clinical Practice, 2017, 23, 37-43. Budesonide/formoterol as maintenance and reliever therapy compared to fixed-budesonide/formoterol plus albuterol reliever for pediatric asthma: A cost-utility analysis in Colombia. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 3816-3818.e2. 3.8 Advantage of inhaled corticosteroids as additional therapy to systemic corticosteroids for pediatric 50 1.7 7 acute asthma exacerbations: a cost-effectiveness analysis. Journal of Asthma, 2020, 57, 949-958. Validation of a new predictive model to improve risk stratification in bronchopulmonary dysplasia. Scientific Reports, 2020, 10, 613. Predictors of response to medications for asthma in pediatric patients: A systematic review of the 52 2.0 7 literature. Pediatric Pulmonology, 2020, 55, 1320-1331. Phenotypical characterization of human rhinovirus infections in severely premature children. Pediatrics and Neonatology, 2018, 59, 244-250. Costâ€utility of omalizumab for the treatment of uncontrolled moderateâ€toâ€severe persistent pediatric 54 2.0 6 allergic asthma in a middleâ€income country. Pediatric Pulmonology, 2021, 56, 2987-2996.

#	Article	IF	CITATIONS
55	Comparison of the bronchodilating effects of albuterol delivered by valved vs. nonâ€valved spacers in pediatric asthma. Pediatric Allergy and Immunology, 2012, 23, 629-635.	2.6	5
56	Children under 12 months could benefit from a therapeutic trial with bronchodilators if the clinical response is positive. Acta Paediatrica, International Journal of Paediatrics, 2015, 104, e540-e540.	1.5	5
57	Validation of the Spanish version of the Pediatric Asthma Caregiver Quality of Life Questionnaire (PACQLQ) in a population of Hispanic children. Journal of Asthma, 2015, 52, 749-754.	1.7	5
58	Age-Related Effect of Viral-Induced Wheezing in Severe Prematurity. Children, 2016, 3, 19.	1.5	5
59	Costâ€effectiveness of the utilization of "good practice―or the lack thereof according to a bronchiolitis evidenceâ€based clinical practice guideline. Journal of Evaluation in Clinical Practice, 2019, 25, 682-688.	1.8	5
60	Reference values for spirometric parameters in healthy children living in a Colombian city located at 2640 m altitude. Pediatric Pulmonology, 2019, 54, 886-893.	2.0	5
61	When adherence and inhalation technique matter: Difficultâ€toâ€control pediatric asthma in Iow―to middleâ€income countries. Pediatric Pulmonology, 2021, 56, 1366-1373.	2.0	5
62	Budget impact analysis of high-flow nasal cannula for infant bronchiolitis: the Colombian National Health System perspective. Current Medical Research and Opinion, 2021, 37, 1627-1632.	1.9	5
63	A cost-effectiveness threshold analysis of a multidisciplinary structured educational intervention in pediatric asthma. Journal of Asthma, 2018, 55, 561-570.	1.7	4
64	Bedside clinical assessment predicts recurrence after hospitalization due to viral lower respiratory tract infection in young children. Journal of Investigative Medicine, 2020, 68, 756-761.	1.6	4
65	Dexamethasone or prednisolone for asthma exacerbations in children: A costâ€effectiveness analysis. Pediatric Pulmonology, 2020, 55, 1617-1623.	2.0	4
66	Efficacy, safety and costâ€effectiveness of hydroxychloroquine in children with COVIDâ€19: A call for evidence. Acta Paediatrica, International Journal of Paediatrics, 2020, 109, 1711-1712.	1.5	4
67	Costâ€effectiveness analysis of phenotypicâ€guided versus guidelinesâ€guided bronchodilator therapy in viral bronchiolitis. Pediatric Pulmonology, 2021, 56, 187-195.	2.0	4
68	Genes, environment, and developmental timing: New insights from translational approaches to understand early origins of respiratory diseases. Pediatric Pulmonology, 2021, 56, 3157-3165.	2.0	4
69	Predictors of poor outcomes of respiratory syncytial virus acute lower respiratory infections in children under 5 years of age in a middleâ€income tropical country based on the National Public Health Surveillance System. Pediatric Pulmonology, 2022, 57, 1188-1195.	2.0	4
70	Impact of pulmonary hypertension and congenital heart disease with hemodynamic repercussion on the severity of acute respiratory infections in children under 5 years of age at a pediatric referral center in Colombia, South America. Cardiology in the Young, 2020, 30, 1866-1873.	0.8	3
71	Adding nebulized corticosteroids to systemic corticosteroids for acute asthma in children: A systematic review with metaâ€analysis. Pediatric Pulmonology, 2020, 55, 2508-2517.	2.0	3
72	Are we overcoming our inability to have pediatric patients properly use inhaled corticosteroids by inappropriately escalating their therapy?. Journal of Asthma, 2022, 59, 1360-1371.	1.7	3

#	Article	IF	CITATIONS
73	Validation of a Spanish version of the Sleepâ€Related Breathing Disorder scale of the Pediatric Sleep Questionnaire in children living in a highâ€altitude city. Pediatric Pulmonology, 2021, 56, 1077-1084.	2.0	3
74	A comparative analysis of the bronchodilatador response measured by impulse oscillometry and spirometry in asthmatic children living at high altitude. Journal of Asthma, 2021, 58, 1488-1494.	1.7	2
75	Commercial valved spacers versus home-made spacers for delivering bronchodilator therapy in pediatric acute asthma: a cost-effectiveness analysis. Journal of Asthma, 2021, 58, 1340-1347.	1.7	2
76	Prediction of normal values for central apnea-hypopnea index at different ages and altitudes above sea level in healthy children. Sleep Medicine, 2021, 78, 182-188.	1.6	2
77	Use of inhaled corticosteroids on an intermittent or as-needed basis inÂpediatric asthma: a systematic review of the literature. Journal of Asthma, 2022, 59, 2189-2200.	1.7	2
78	As-Needed Use of Short-Acting β2-Agonists Alone Versus As-Needed Use of Short-Acting β2-Agonists Plus Inhaled Corticosteroids in Pediatric Patients With Mild Intermittent (Step 1) Asthma: A Cost-Effectiveness Analysis. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 1562-1568.	3.8	2
79	Efficacy and Safety of Valsartan or Chlorthalidone vs. Combined Valsartan and Chlorthalidone in Patients With Mild to Moderate Hypertension: The VACLOR Study. Clinical Medicine Insights: Cardiology, 2018, 12, 117954681879648.	1.8	1
80	Development of spirometric reference equations for children living at high altitude. Clinical Respiratory Journal, 2020, 14, 1011-1017.	1.6	1
81	Nebulization procedures for children with unknown viral status during the COVID-19 pandemic. Journal of Asthma, 2021, 58, 1597-1598.	1.7	1
82	The use of ipratropium bromide for treating moderate to severe asthma exacerbations in pediatric patients in an emergency setting: A costâ€effectiveness analysis. Pediatric Pulmonology, 2021, 56, 3706-3713.	2.0	1
83	Characterization of the variability of care for acute severe asthma: An opportunity for quality improvement initiatives. Pediatric Pulmonology, 2021, 56, 809-810.	2.0	1
84	Disease burden and vaccination priorities in Colombia. Vaccine, 2022, 40, 1717-1721.	3.8	1
85	Emergency departmentâ€initiated home oxygen for viral bronchiolitis: A costâ€effectiveness analysis. Pediatric Pulmonology, 2022, 57, 2154-2160.	2.0	1
86	Response to letter. Pediatric Pulmonology, 2021, 56, 2783-2784.	2.0	0
87	To the Editor. Sleep Medicine, 2021, 86, 124.	1.6	0